Skip to the page

Data / Drug companies / Chongqing Daxin Pharmaceutical Co. Ltd.

Chongqing Daxin Pharmaceutical Co. Ltd.: 14 products in the FDA NDC directory, labeler code 57885

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Chongqing Daxin Pharmaceutical Co. Ltd. (labeler code 57885) lists 14 products in the FDA National Drug Code Directory. By type: 14 bulk ingredients. Its main marketing category is bulk ingredients. The newest product started marketing on June 1, 2026.

The request: Watch Chongqing Daxin Pharmaceutical Co. Ltd. (FDA labeler code 57885): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
57885
Products in commercial distribution
14
Packages
16
Finished drugs by generic name
0
Prescription products
0
Over the counter products
0
Started marketing in the last 12 months
1
Earliest marketing start
July 28, 2010
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Bulk ingredients1392.9%
Bulk ingredients for compounding17.1%

Products by type

TypeProductsShare
Bulk ingredients14100%

Dosage forms

Dosage formProductsShare
Powder14100%

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Sirolimus57885-0014PowderBulk ingredients for compoundingJune 1, 2026
Lovastatin57885-0008PowderBulk ingredientsJuly 1, 2025
Mycophenolate sodium57885-0021PowderBulk ingredientsJuly 1, 2024
Mycophenolate oxime57885-0020PowderBulk ingredientsJuly 1, 2024
Milbemycin oxime57885-0016PowderBulk ingredientsJanuary 1, 2020
Mevastatin57885-0015PowderBulk ingredientsJanuary 1, 2020
Sirolimus57885-0014PowderBulk ingredientsJanuary 1, 2020
Vancomycin hcl57885-0012PowderBulk ingredientsJanuary 1, 2020
Daptomycin57885-0011PowderBulk ingredientsJanuary 1, 2020
Mycophenolic acid57885-0009PowderBulk ingredientsJanuary 1, 2020
Lovastatin57885-0008PowderBulk ingredientsOctober 30, 2019
Doramectin57885-0017PowderBulk ingredientsMay 21, 2019
Moxidectin57885-0010PowderBulk ingredientsOctober 8, 2013
Tobramycin57885-0002PowderBulk ingredientsJuly 28, 2010

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.